Advertisement
Free access | 10.1172/JCI108865
Mineral Research Laboratory, Department of Medicine, Mayo Clinic and Mayo Medical School, Rochester, Minnesota 55901
Division of Endocrinology, Department of Medicine, Mayo Clinic and Mayo Medical School, Rochester, Minnesota 55901
Find articles by Heath, H. in: JCI | PubMed | Google Scholar
Mineral Research Laboratory, Department of Medicine, Mayo Clinic and Mayo Medical School, Rochester, Minnesota 55901
Division of Endocrinology, Department of Medicine, Mayo Clinic and Mayo Medical School, Rochester, Minnesota 55901
Find articles by Sizemore, G. in: JCI | PubMed | Google Scholar
Published November 1, 1977 - More info
We measured plasma calcitonin concentrations in healthy volunteers (20 men, ages 23-45 yr, mean, 30 yr; 25 women, ages 21-46 yr, mean, 30 yr) with a radioimmunoassay capable of detecting 5 pg of calcitonin/500 μl incubation volume, or 25 pg/ml of unextracted plasma. All subjects had 4-h calcium infusion (15 mg Ca/kg), and 24 subjects had intravenous pentagastrin injection (0.5 μg/kg) on separate days. Men had higher basal plasma immunoreactive calcitonin concentrations than women (P < 0.001): mean, 49 pg/ml (range, <25-73) and 31 pg/ml (range, <25-51), respectively. 18 of the 20 men (90%) responded to induced hypercalcemia with increases in plasma immunoreactive calcitonin; only 14 of the 25 women (56%) responded. In men, the mean increase of plasma immunoreactive calcitonin±SE was 58±9 pg/ml, but for women was only 25±6 pg/ml. 8 of 10 men (80%) responded to pentagastrin with an increase of plasma immunoreactive calcitonin >30 pg/ml, compared with such a response in only 1 of 14 women (7%). These differences of plasma immunoreactive calcitonin responses between the sexes were statistically significant (calcium infusion, P < 0.02; pentagastrin, P < 0.001). The physiologic importance of these observations is unknown, but we speculate that a lifelong, relative deficiency of calcitonin in some women could play a role in age- and sex-related bone loss, particularly during the estrogen-deficient postmenopausal years.